| http://www.w3.org/ns/prov#value | - For cancers that can not be all cut out, the best options are to pursue enrollment on a clinical trial (usually a chemotherapy based clinical trial) or to receive the chemotherapy off-label (i.e. none of the chemo drugs will be FDA approved for papillary RCC, as it is a very rare cancer--i.e. between 6-15% incidence).
|
